MacroGenics (MGNX) Competitors $1.59 -0.06 (-3.64%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.31%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. ZVRA, PRME, BCYC, EOLS, REPL, CMPS, RGNX, ARCT, CMPX, and ETONShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Zevra Therapeutics (ZVRA), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), Evolus (EOLS), Replimune Group (REPL), COMPASS Pathways (CMPS), REGENXBIO (RGNX), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Its Competitors Zevra Therapeutics Prime Medicine Bicycle Therapeutics Evolus Replimune Group COMPASS Pathways REGENXBIO Arcturus Therapeutics Compass Therapeutics Eton Pharmaceuticals Zevra Therapeutics (NASDAQ:ZVRA) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment. Does the media prefer ZVRA or MGNX? In the previous week, Zevra Therapeutics had 3 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Zevra Therapeutics and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 1.53 beat Zevra Therapeutics' score of 1.43 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend ZVRA or MGNX? Zevra Therapeutics presently has a consensus price target of $23.71, indicating a potential upside of 205.99%. MacroGenics has a consensus price target of $3.60, indicating a potential upside of 126.42%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89MacroGenics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.57 Do insiders & institutionals believe in ZVRA or MGNX? 35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 13.0% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings and valuation, ZVRA or MGNX? MacroGenics has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$23.61M18.42-$105.51M-$0.21-36.90MacroGenics$149.96M0.67-$66.97M-$0.57-2.79 Which has more volatility and risk, ZVRA or MGNX? Zevra Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Is ZVRA or MGNX more profitable? Zevra Therapeutics has a net margin of 4.33% compared to MacroGenics' net margin of -21.99%. MacroGenics' return on equity of -40.24% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics4.33% -112.40% -37.67% MacroGenics -21.99%-40.24%-14.62% SummaryMacroGenics beats Zevra Therapeutics on 10 of the 17 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.29M$10.93B$5.86B$10.15BDividend YieldN/A1.84%5.68%4.59%P/E Ratio-2.7921.1374.5225.93Price / Sales0.6731.03536.78122.58Price / CashN/A24.8137.5660.44Price / Book0.863.5212.166.29Net Income-$66.97M$210.50M$3.28B$270.77M7 Day Performance-20.50%-0.18%0.98%3.36%1 Month Performance8.16%3.91%7.20%6.41%1 Year Performance-55.96%-10.02%63.06%28.26% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics4.4735 of 5 stars$1.59-3.6%$3.60+126.4%-54.4%$104.29M$149.96M-2.79430Positive NewsZVRAZevra Therapeutics2.8628 of 5 stars$8.33-6.9%$23.71+184.7%+7.6%$502.41M$23.61M-39.6720Positive NewsPRMEPrime Medicine3.2834 of 5 stars$3.89+4.6%$8.92+129.2%-0.2%$500.62M$4.96M-1.90234BCYCBicycle Therapeutics3.6263 of 5 stars$7.00-2.2%$22.22+217.5%-74.0%$495.86M$35.28M-1.99240Positive NewsEOLSEvolus4.1963 of 5 stars$7.61-0.7%$21.25+179.2%-50.8%$495.49M$266.27M-7.77170Short Interest ↓REPLReplimune Group3.9106 of 5 stars$6.04-4.6%$6.50+7.6%-42.0%$494.09MN/A-1.86210Trending NewsCMPSCOMPASS Pathways3.2148 of 5 stars$4.98-3.1%$16.29+227.0%-23.5%$493.14MN/A-2.71120Positive NewsRGNXREGENXBIO4.6608 of 5 stars$9.48-2.4%$28.38+199.3%-25.3%$490.49M$83.33M-2.76370ARCTArcturus Therapeutics3.1395 of 5 stars$17.84-0.1%$50.57+183.5%-14.0%$484.72M$109.80M-8.00180Positive NewsGap DownCMPXCompass Therapeutics2.4007 of 5 stars$3.44flat$12.89+274.7%+135.3%$475.69M$850K-7.6420Positive NewsETONEton Pharmaceuticals1.9929 of 5 stars$17.78+0.6%$29.67+66.9%+266.8%$473.87M$39.01M-111.1320Positive News Related Companies and Tools Related Companies Zevra Therapeutics Alternatives Prime Medicine Alternatives Bicycle Therapeutics Alternatives Evolus Alternatives Replimune Group Alternatives COMPASS Pathways Alternatives REGENXBIO Alternatives Arcturus Therapeutics Alternatives Compass Therapeutics Alternatives Eton Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGNX Stock Alerts